237 related articles for article (PubMed ID: 10908844)
1. Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Albanell J; Tabernero JM; Cortés-Funes H; Baselga J
Eur J Cancer; 2000 Jul; 36 Suppl 2():17-25. PubMed ID: 10908844
[TBL] [Abstract][Full Text] [Related]
2. Current and future perspectives in advanced bladder cancer: is there a new standard?
von der Maase H
Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Sternberg CN; Calabrò F; Pizzocaro G; Marini L; Schnetzer S; Sella A
Cancer; 2001 Dec; 92(12):2993-8. PubMed ID: 11753976
[TBL] [Abstract][Full Text] [Related]
4. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J;
Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Halim A; Abotouk N
Asia Pac J Clin Oncol; 2013 Mar; 9(1):60-5. PubMed ID: 22897883
[TBL] [Abstract][Full Text] [Related]
8. Novel gemcitabine-containing triplets in the management of urothelial cancer.
Hussain M; Vaishampayan U; Smith DC
Semin Oncol; 2002 Feb; 29(1 Suppl 3):20-4. PubMed ID: 11894004
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Bellmunt J; Albiol S; de Olano AR; Pujadas J; Maroto P;
Ann Oncol; 2006 May; 17 Suppl 5():v113-7. PubMed ID: 16807437
[TBL] [Abstract][Full Text] [Related]
10. Palliative chemotherapy in advanced bladder cancer.
Roth BJ
Semin Oncol; 1995 Apr; 22(2 Suppl 3):10-5. PubMed ID: 7537896
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer.
von der Maase H
Eur J Cancer; 2000 Jul; 36 Suppl 2():13-6. PubMed ID: 10908843
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine doublets in advanced urothelial cancer.
Stadler WM
Semin Oncol; 2002 Feb; 29(1 Suppl 3):15-9. PubMed ID: 11894003
[TBL] [Abstract][Full Text] [Related]
13. New chemotherapy combinations for advanced bladder cancer.
Bellmunt J; Albiol S
Curr Opin Urol; 2001 Sep; 11(5):517-22. PubMed ID: 11493774
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Roberts JT; von der Maase H; Sengeløv L; Conte PF; Dogliotti L; Oliver T; Moore MJ; Zimmermann A; Arning M
Ann Oncol; 2006 May; 17 Suppl 5():v118-22. PubMed ID: 16807438
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
Kanai K; Kikuchi E; Ohigashi T; Miyajima A; Nakagawa K; Nakashima J; Oya M
Int J Clin Oncol; 2008 Dec; 13(6):510-4. PubMed ID: 19093178
[TBL] [Abstract][Full Text] [Related]
16. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Ichioka D; Miyazaki J; Inoue T; Kageyama S; Sugimoto M; Mitsuzuka K; Matsui Y; Shiraishi Y; Kinoshita H; Wakeda H; Nomoto T; Kikuchi E; Nishiyama H
Jpn J Clin Oncol; 2015 Sep; 45(9):867-73. PubMed ID: 26056328
[TBL] [Abstract][Full Text] [Related]
17. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
19. The present and future of combination chemotherapy in bladder cancer.
Culine S
Semin Oncol; 2002 Jun; 29(3 Suppl 9):32-9. PubMed ID: 12094336
[TBL] [Abstract][Full Text] [Related]
20. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Oing C; Rink M; Oechsle K; Seidel C; von Amsberg G; Bokemeyer C
J Urol; 2016 Feb; 195(2):254-63. PubMed ID: 26410730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]